Could Vaccination against COVID-19 Trigger Immune-Mediated Inflammatory Diseases?-Reference-Cited by-同舟云学术

Could Vaccination against COVID-19 Trigger Immune-Mediated Inflammatory Diseases?

Published:2024-08-07 Issue:16 Volume:13 Page:4617
ISSN:2077-0383
Container-title:Journal of Clinical Medicine
language:en
Short-container-title:JCM

Author:

Liakou Aikaterini I.¹^ORCID,Tsantes Andreas G.²³^ORCID,Routsi Eleni¹^ORCID,Agiasofitou Efthymia¹,Kalamata Magdalini¹,Bompou Evangelia-Konstantina¹,Tsante Konstantina A.²,Vladeni Soultana¹,Chatzidimitriou Eleni¹,Kotsafti Ourania¹^ORCID,Samonis George⁴⁵,Bonovas Stefanos⁶⁷^ORCID,Stratigos Alexander I.¹

Affiliation:

1. 1st Department of Dermatology-Venereology, “Andreas Sygros” Hospital, National and Kapodistrian University of Athens Medical School, 16121 Athens, Greece

2. Laboratory of Haematology and Blood Bank Unit, “Attikon” Hospital, National and Kapodistrian University of Athens Medical School, 12462 Athens, Greece

3. Microbiology Department, “Saint Savvas” Oncology Hospital, 11522 Athens, Greece

4. Department of Medicine, University of Crete, 71500 Heraklion, Greece

5. Department of Oncology, Metropolitan Hospital, 18547 Athens, Greece

6. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Milan, Italy

7. IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy

Abstract

Exacerbations and new onset of immune-mediated inflammatory diseases, such as psoriasis and hidradenitis suppurativa, have been reported following COVID-19 vaccination. In patients with hidradenitis suppurativa, recent studies have shown that those who received mRNA vaccines were 3.5 times as likely to develop flares following vaccination compared to patients who received non-mRNA vaccines, indicating that mRNA COVID-19 vaccines are associated with hidradenitis suppurativa flares. Similar findings have been found in other studies evaluating the association between COVID-19 vaccines and other immune-mediated inflammatory diseases such as psoriasis, atopic dermatitis, lichen planus, and alopecia areata. However, further research is warranted in larger populations to validate these findings.

Publisher

MDPI AG

Link

https://www.mdpi.com/2077-0383/13/16/4617/pdf

Reference56 articles.

1. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine;Polack;N. Engl. J. Med.,2020

2. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK;Voysey;Lancet,2021

3. A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders;Seirafianpour;Dermatol. Ther.,2022

4. Management of patients with hidradenitis suppurativa during COVID-19 vaccination: An experience from Southern Italy;Fabrizio;Clin. Exp. Dermatol.,2022

5. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort;Venturi;J. Eur. Acad. Dermatol. Venereol.,2021